Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer
/in International Publications, Ovarian Cancer /von 2002-04-01 / Minerva Ginecol 2002 Apr;54(2):133-44Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer
/in International Publications, Ovarian Cancer /von 2002-02-01 / Expert Rev Anticancer Ther 2002 Feb;2(1):97-105Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial
/in Dendritic Cells, Endometrial Cancer, International Publications, Ovarian Cancer /von 2002-01-10 / Cancer Immunol. Immunother. 2002 Mar;51(1):45-52Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer
/in Dendritic Cells, Endometrial Cancer, International Publications, Ovarian Cancer /von 2002-01-07 / Br. J. Cancer 2002 Jan;86(1):151-7Dendritic cells in cancer vaccines
/in International Publications, Ovarian Cancer /von 2001-11-01 / Exp. Hematol. 2001 Nov;29(11):1247-55Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
/in Breast Cancer, Dendritic Cells, International Publications, Ovarian Cancer /von 2000-11-01 / Blood 2000 Nov;96(9):3102-8A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
/in Breast Cancer, Colorectal Cancer, Dendritic Cells, International Publications, Ovarian Cancer, Pancreatic Cancer /von 1999-06-01 / Clin. Cancer Res. 1999 Jun;5(6):1331-8Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer
/in Breast Cancer, International Publications, Newcastle Disease Virus, Ovarian Cancer /von 1997-04-01 / J. Clin. Oncol. 1997 Apr;15(4):1354-66
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus
- Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
- A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma